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Amiodarone is an antiarrhythmic drug which is highly effective against a wide spectrum of ventricular tachyarrhythmias making
it irreplaceable in certain group of patients. We report an unusual case of acute liver and renal failure within 24 hours of initiation
of intravenous (IV) amiodarone which resolved after stopping the medication. The mechanism of acute liver and renal toxicity is
not clearly known but is believed to be secondary to amiodarone induced (relative) hypotension, idiosyncratic reaction to the drug,
and toxicity of the vector that carries the medication, polysorbate-80. In this case review, we discuss the hyperacute drug toxicity
caused by IV amiodarone being a distinctly different entity compared to the adverse effects shown by oral amiodarone and support
the suggestion that oral amiodarone can be safely administered even in patients who manifest acute hepatitis with the IV form.

1. Introduction
Amiodarone is a class III antiarrhythmic drug highly effective
against a wide spectrum of ventricular tachyarrhythmias.
We report an unusual case of acute liver and renal failure
within 24 hours of initiation of intravenous (IV) amiodarone.
Despite wide popularity and efficacy of amiodarone in the
treatment of various kinds of cardiac arrhythmias, little is
understood about the mechanisms by which IV amiodarone
can lead to acute liver and renal failure. As a result, most of
the physicians end up withholding this medication altogether.
In this case review, we discuss the hyperacute drug toxicity
caused by IV amiodarone being a distinctly different entitycompared to the adverse effects shown by oral amiodarone
and support the suggestion that oral amiodarone can be safely
administered even in patients who manifest acute hepatitis
with the IV form.

2. Case Summary
65-year-old Caucasian male with past medical history of
Coronary Artery Disease (CAD) status post Coronary Artery
Bypass Graft Surgery (CABG), Ischemic Cardiomyopathy

status post Automatic Implantable Cardioverter Defibrillator
(AICD), hypertension, and dyslipidemia presented to the
emergency room (ER) with complaints of multiple AICD
shocks. In the ER, he was hemodynamically stable and in no
acute distress. His physical examination was unremarkable
and had no signs of decompensated heart failure. His initial
set of labs at presentation that included Complete Blood
Count (CBC), Basic Metabolic Panel (BMP), and Liver Function Test (LFT) were within normal limits. Echocardiogram
showed severely dilated left ventricle with ejection fraction
of 23%. Patient was loaded with amiodarone 150 mg IV
followed by amiodarone drip (1 mg/min for first 6 hours and
then 0.5 mg/min for next 18 hours). Patient received total
of 1050 mg. Patient was continued on his home medications
(Docusate 100 mg three times a day as needed, aspirin
81 mg daily, clopidogrel 75 mg daily, famotidine 20 mg two
times a day, escitalopram 10 mg daily, valsartan 80 mg daily,
metoprolol succinate 100 mg daily, ezetimibe 10 mg daily,
and simvastatin 80 mg daily). In addition, he also received
enoxaparin 40 mg daily and zolpidem 5 mg daily.
His BP at presentation was 140/88(MAP 105) which
dropped to the lowest, 90/60(MAP 70), over the initial 5 to
6 hours of starting amiodarone and remained in that range

2

Case Reports in Critical Care
Duration for which amiodarone drip was given

Session of hemodialysis
2.5
Creatinine level (mg/dL)

10000
9000
8000
Value (U/L)

7000
6000
5000
4000
3000

2
1.5
1
Duration for which amiodarone was given
0.5
0

2000

0

12

24

36

1000
0

0

12

24

36

48

60

72

84

96 108 120 132 144

Time (hours)

48

60 72 84
Time (hours)

96

108 120 132

Creatinine

Figure 2: Worsening renal function after IV amiodarone.
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Figure 1: Elevation of liver enzymes after IV amiodarone.

for 2 to 3 hours. It then improved to MAP of 70–75 but
remained lower than his baseline MAP around 100. During
the last one-third duration of the amiodarone drip, patient
had another period of hypotension with the lowest systolic BP
of 86 and diastolic BP of 49 with MAP ranging from 61 to 75
lasting for a period of 3 hours. All other causes of hypotension
including sepsis, hypovolemia, and cardiac arrhythmia were
ruled out. His blood pressure began to improve 2 hours
after stopping amiodarone. However, labs showed dramatic
changes. Lab works done one day after starting amiodarone
showed marked increase in WBC, potassium, LFTs (Figure 1),
and creatinine (Figure 2). Patient became oliguric and hyperkalemic requiring emergent hemodialysis. Ultrasound of the
right upper quadrant of the abdomen showed normal liver
architecture, workup for viral hepatitis was negative, and
sepsis was ruled out.
Patient was monitored in the hospital over 5 days for
downward trend of LFTs and creatinine and was discharged
home with arrangements for further follow-up plans. After
one month, oral amiodarone was started which was well
tolerated by the patient with follow-up lab works done at 6
months showing normal values.

3. Discussion
Amiodarone is an iodinated-benzofuran class III antiarrhythmic drug which is highly effective against a wide spectrum
of ventricular tachyarrhythmias. Amiodarone is notoriously
known to cause various adverse effects including but not
limited to liver toxicity, hypo- or hyperthyroidism, QT prolongation, Atrioventricular (AV) block, severe hypotension,
Acute Respiratory Distress Syndrome (ARDS), cardiogenic
shock, pulmonary fibrosis, and visual disturbance. Amiodarone, being extremely lipophilic, enters the tissues easily
and accumulates in the cells including hepatocytes. With a
half-life of around 6 months, most of the common serious
adverse effects are mainly seen on long term use, oral route
being the mode of administration. Amiodarone is initially

given at a higher dosage orally or IV termed as the loading
dose followed by a daily maintenance dose orally. While most
of the known toxic effects of amiodarone is seen on prolonged
oral use, most acute adverse effects are observed with the
intravenous use of the medication. For unknown reasons,
few of the rare side effects that include acute liver failure,
cardiac arrest, ARDS, renal injury, and hypotension are
almost exclusively seen with the intravenous administration
of amiodarone and not with oral loading or maintenance
dosing of amiodarone [1–4]. We have presented one such rare
case of acute liver and renal failure secondary to intravenous
amiodarone administration. The diagnosis of amiodarone
toxicity was made based on a thorough drug history excluding any other hepatotoxic agents and other causes of hepatitis,
complete physical examination, laboratory investigation, and
the temporal relationship with amiodarone administration
and rapid improvement in liver/renal function after stopping
amiodarone.
Hepatotoxicity caused by oral amiodarone is well documented with around 15–20% patients on amiodarone shown
to have elevation in levels of transaminases [2, 5–7]. It can
lead to 1.5- to 4-fold increase in the level of amino transferases
(AST/ALT) while there will be minimal increase in Gamma
Glutamyl Transferase (GGT) and generally no change in
the level of bilirubin and alkaline phosphatase [5]. Despite
elevation of the liver enzymes, clinically significant liver
injury warranting discontinuation of amiodarone remains
low at around 1%.
On the other hand, intravenous (IV) amiodarone toxicity
can raise AST/ALT up to 100–200-fold (AST of 8981 and ALT
of 4450 in our case) within a day of infusion which then
reverses quickly after discontinuation of amiodarone except
for a few reported cases of fatal hepatotoxicity [8, 9]. There
have been case reports where patients who manifested acute
hepatotoxicity when started on IV amiodarone tolerated the
oral amiodarone quite well and manifested acute toxicity
when IV form was reintroduced [10, 11]. While the toxicity
from chronic oral amiodarone is believed to be due to
direct damage to the lipid bilayers and the disturbance of
lysosomal and mitochondrial function, the acute toxicity
due to IV amiodarone is believed to be due to different
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mechanisms like hypersensitivity reaction, relative hypotension causing ischemic liver injury [10, 12, 13], toxicity of
the vehicle (polysorbate-80) [11, 14, 15], and idiosyncratic
toxicity. Centrilobular necrosis and collapse with minimal
inflammation and no appreciable fat as seen in these patients
with acute liver toxicity with intravenous amiodarone toxicity
suggest ischemic cause of liver injury. Ischemic liver injury
is understood to be caused by relative hypotension in the
setting of congestive hepatopathy secondary to underlying
congestive heart failure which most of the patients needing amiodarone would probably have. Our patient did not
have increase in eosinophils count in the blood which
points against hypersensitivity reaction. The fact that the
mean arterial pressure (MAP) dropped on average by 30–
40 mm Hg compared to his baseline favors the etiology being
ischemic. His BP remained low throughout the course of
amiodarone administration only to improve after stopping
amiodarone.
There is also some literature suggestive of the vehicle polysorbate-80 as the cause behind the acute toxicity
seen in intravenous amiodarone administration [11, 14, 15].
Polysorbate-80 or polyoxyethylene-sorbitan-20 monooleate
(C64H124O26) is a vehicle used to make the stable solution
form of amiodarone for intravenous use. Polysorbate-80 has
been shown to have similar hepatotoxic and nephrotoxic
effect, popularly known as E-ferol syndrome [14–19] seen in
the infants who get intravenous form of vitamin E which
contains polysorbate-80 and polysorbate-20.
Not much has been studied about the kidney injury seen
in amiodarone. Fogoros et al. [5] reported that about 8.8% of
patients on oral amiodarone had an elevation of creatinine
with a mean increase of 0.81 mg/dL with one among them
requiring discontinuation of the medication. The mechanism
behind renal injury due to amiodarone is not clearly understood with renal failure secondary to rhabdomyolysis and
cardiorenal syndrome due to drop in blood pressure being the
proposed mechanisms. In our patient, cardiorenal syndrome
is the most likely mechanism.
Although acute toxic effect due to intravenous amiodarone is rare, but occurred once, it creates a true dilemma
in the physician’s mind regarding its future use in the patient.
While failure to recognize acute toxicity of IV amiodarone
can be detrimental, unnecessary avoidance of amiodarone
can preclude a patient from getting a potentially lifesaving medication. Our case, for instance, presented with 16
episodes of sustained ventricular tachycardia, 10 of them
being terminated by AICD firing and the need for effective
antiarrhythmic cannot be overemphasized.
Etiology behind acute toxicity associated with IV amiodarone is still not completely understood. However, irrespective of the etiology, taking into consideration that the acute
toxicity of IV amiodarone is a distinctly different entity from
the chronic toxicities of oral amiodarone, we support the
recommendation not to withhold the potentially lifesaving
oral amiodarone after the patient has an acute toxicity due
to IV amiodarone. Oral amiodarone can be safely started
once the liver enzymes normalize [10, 11, 15], as done in our
patient, although further monitoring of the liver enzymes is
recommended once the patient is started on oral amiodarone.
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Additional Points
Objective. We report a case of acute liver and renal failure
induced by intravenous amiodarone and review of similar
cases.
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